Blood and Marrow Transplant and Cellular Therapy Clinical Trials

Cedars-Sinai is committed to research that leads to better treatments and return to normal life.

Questions? See the Clinical Trials FAQs.

Title:

Bendamustine, Fludarabine, and Rituximab Conditioning for Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion for Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL

Condition/Intervention:

  • Lymphoma, multiple myeloma, chronic lymphocytic leukemia

Summary:

In this study, individuals who are undergoing allogeneic stem cell transplantation for lymphoma or chronic lymphocytic leukemia will receive a low-dose, conditioning regimen before transplantation, combined with post-transplant treatment (chemotherapy to reduce the risk of developing graft-versus-host disease).

Title:

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (Mm) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC STUDY)

Condition/Intervention:

  • Multiple myeloma

Summary:

Patients with multiple myeloma who have had a stem cell transplant are eligible for this study. The purpose of the study is to determine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment (lenalidomide) after stem cell transplant will help these patients live longer.

Title:

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Condition/Intervention:

  • Acute myeloid leukemia

Summary:

Patients with multiple myeloma who have had a stem cell transplant are eligible for this study. The purpose of the study is to determine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment (lenalidomide) after stem cell transplant will help these patients live longer.

Title:

Research Tissue Bank Myeloproliferative Neoplasms Research Consortium

Condition/Intervention:

  • Myelofibrosis

Summary:

In this study, myelofibrosis patients will provide small samples of blood and toenail clippings to be stored for current and future research. Researchers will use the samples to improve the diagnosis and treatment of myelofibrosis, as well as to learn more about the causes of the disease.

Title:

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Condition/Intervention:

  • Lymphoma

Summary:

Participants in this study have a type of diffuse large B-cell lymphoma (activated B-cell subtype) that did not improve with treatment or has returned after previous treatment. The goal of the study is to determine whether adding a drug called ibrutinib to the usual chemotherapy given with autologous hematopoietic stem cell transplantation (AutoHCT) could prevent the patient’s lymphoma from returning.

Title:

ION251-CS1: A Phase I Study of ION251 Administered by Intravenous Infusion to Patients With Relapsed/Refractory Multiple Myeloma (IRB no. 00000972)

Condition/Intervention:

  • Multiple myeloma

Summary:

This study is designed to examine the safety and tolerability of multiple doses of an experimental drug called ION251 when given by intravenous (IV) infusion to patients who have been diagnosed with relapsed or refractory multiple myeloma (myeloma that has returned or has not responded to treatment).


Title:

Blinatumomab Plus HLA Mismatched Cellular Therapy (HMCT) for Relapsed Refractory CD19+ ALL

Condition/Intervention:

  • Acute lymphoblastic leukemia

Summary:

This study focuses on patients who have CD 19+ acute lymphoblastic leukemia that has relapsed or has not responded to previous therapy. The study aims to evaluate the safety and effectiveness of combining haplo-mismatched cellular therapy with a drug called blinatumomab. Participants must have a family member who is able to donate peripheral blood cells.